- Home
- RLYB vs MRDN Comparison
RLYB vs MRDN Comparison
Compare RLYB & MRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | MRDN |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | 1200 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.9M | 83.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLYB | MRDN |
|---|---|---|
| Price | $15.68 | $9.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 312.9K | 72.2K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $858,000.00 | N/A |
| Revenue This Year | N/A | $16.30 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.27 | $6.01 |
| 52 Week High | $16.00 | $16.09 |
Technical Indicators
Market Signals| Indicator | RLYB | MRDN |
|---|---|---|
| Relative Strength Index (RSI) | 74.89 | 51.11 |
| Support Level | $0.55 | $9.72 |
| Resistance Level | $15.31 | $11.84 |
| Average True Range (ATR) | 0.69 | 1.57 |
| MACD | 0.05 | -0.21 |
| Stochastic Oscillator | 71.13 | 18.79 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
About MRDN Meridian Holdings Inc. Common Stock
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.